Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Baudax Bio Reports 2019 Annual Financial Results
09:08pm, Thursday, 13'th Feb 2020
FDA Grants Appeal for IV Meloxicam New Drug Application PDUFA Goal Date of February 20, 2020 MALVERN, Pa., Feb. 13, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a.
Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
06:30pm, Monday, 03'rd Feb 2020
Biotech stocks have come under some selling pressure in the new year. However, January did witness some strong stock-specific upward moves, especially with stocks leveraged to the Wuhan coronavirus ep
The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
12:43pm, Friday, 24'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
12:00pm, Wednesday, 22'nd Jan 2020
Baudax Bio, Inc. (BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date
